Food and Drug Administration’s Role in Dermatology, An Issue of Dermatologic Clinics
- 1st Edition, Volume 40-3 - June 24, 2022
- Latest edition
- Editor: Markham C. Luke
- Language: English
In this issue, guest editors bring their considerable expertise to this important… Read more
Purchase options
Description
Description
In this issue, guest editors bring their considerable expertise to this important topic.
Key features
Key features
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Table of contents
Table of contents
The History of Dermatology and Dermatologists at the US Food and Drug Administration
The Food and Drug Administration’s Role in Dermatologic Drug Development
Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions
How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?
Dermatology Drugs for Children—U.S. Food and Drug Administration Perspective
Regulation of Medical Devices for Dermatology
Regulation of Cosmetics in the United States
Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products
Measuring What Matters to Patients in Dermatology Drug Development: A Regulatory Perspective
The Food and Drug Administration’s Role in Dermatologic Drug Development
Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions
How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?
Dermatology Drugs for Children—U.S. Food and Drug Administration Perspective
Regulation of Medical Devices for Dermatology
Regulation of Cosmetics in the United States
Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products
Measuring What Matters to Patients in Dermatology Drug Development: A Regulatory Perspective
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 40-3
- Published: June 27, 2022
- Language: English
About the editor
About the editor
ML
Markham C. Luke
Affiliations and expertise
Food and Drug Administration